Despite promising preclinical data, only a few new antiseizure drugs have been approved for treatment of epilepsy in recent years and the proportion of treatment-resistant patients has not decreased. One of the reasons is the lack of translational animal models. Traditional epilepsy models heavily rely on systemic application of chemoconvulsants as seizure initiating events, which oftentimes create widespread damage to the CNS. A focus has been placed on the mere occurrence of the main symptom of epilepsy - spontaneous, recurrent seizures. However, the clinical etiology of seizures, such as traumatic brain injuries, infections of the CNS, genetic causes, and neonatal conditions, such as hypoxia, fever, or malformations, have not played a major role in model selection. Furthermore, the focal nature of the majority of epileptic seizures and their corresponding neuropathology have been neglected. Including these parameters in model selection could improve the translational value of the data. Lastly, animal experiments overall could be reduced by implementing better in vitro screening methods to identify promising antiseizure compounds. This Method Collection aims to present a variety of animal or in vitro models that are currently being used to investigate (1) the mechanisms leading to seizures, disease progression, and comorbidities of epilepsy, as well as (2) models and techniques that enable compound screening and efficacy testing for clinical translation. The objective of the collection is to guide researchers to the best model for their specific research questions and to help in identifying models that will facilitate translation of findings into the clinic.